Need help? Our team of experienced experts is here for you with full support.
Cat. No.
AKA-388
CAS No.
2803478-47-7
MF
C17H18N6.1/2C4H4O4
MW
728.80
Ruxolitinib Hemifumarate is a selective Janus kinase (JAK) 1 and JAK2 inhibitor belonging to the pyrrolopyrimidine class of compounds.
Ruxolitinib Hemifumarate
2803478-47-7
C17H18N6.1/2C4H4O4
728.80
98.0%~102.0%
Certificate of Analysis (COA), API specification sheet, Safety Data Sheet (SDS/MSDS), evidence of GMP compliance, Stability data / Stability summary, etc.
Ruxolitinib Hemifumarate is a selective Janus kinase (JAK) 1 and JAK2 inhibitor belonging to the pyrrolopyrimidine class of compounds. Packing: 100g/bag,500g/bag,1kg/bag,5kg/bag Availability: In stock API Current Development Status: A3---Process Development / Scale-Up Reference: Aktin major API development processes: A1.Feasibility / Route Development A2.Laboratory Process Development A3.Process Development / Scale-Up A4.GMP Clinical Development A5.Commercial GMP Supply
[1].Lin Q, Meloni D, Pan Y, Xia M, Rodgers J, Shepard S, et al. Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction. Org Lett. 2009;11(9):1999-2002. doi:10.1021/ol900350k.
[2].Crystalline forms of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile salts and preparation thereof. International patent WO2017125097A1. 2017.
[3].Novel polymorph of ruxolitinib hemifumarate and method of preparation. International patent WO2024172778A1. 2024.
[4].Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109-17. doi:10.1182/blood-2009-04-214957.
The information provided on generic APIs is for general reference and market assessment purposes only. Regulatory status, market availability, specifications, patents, and commercial terms may vary by country and change over time. Users should independently verify all information with the relevant regulatory authorities and qualified professionals before making any regulatory, manufacturing, investment, or commercial decisions. We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
* Some statements have not been evaluated by national authorities. * Some products are not intended to diagnose, treat, cure, or prevent any disease. * For literature supporting, please contact us directly.